


Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

<http://hdl.handle.net/2027/mdp.39015072932935>

HathiTrust



www.hathitrust.org

Public Domain, Google-digitized

http://www.hathitrust.org/access_use#pd-google

We have determined this work to be in the public domain, meaning that it is not subject to copyright. Users are free to copy, use, and redistribute the work in part or in whole. It is possible that current copyright holders, heirs or the estate of the authors of individual portions of the work, such as illustrations or photographs, assert copyrights over these portions. Depending on the nature of subsequent use that is made, additional rights may need to be obtained independently of anything we can address. The digital images and OCR of this work were produced by Google, Inc. (indicated by a watermark on each page in the PageTurner). Google requests that the images and OCR not be re-hosted, redistributed or used commercially. The images are provided for educational, scholarly, non-commercial purposes.

HE 20-4210 : 984 / SUPP. 3

THE UNIVERSITY
OF MICHIGAN

MAR 31 1983

MEDICAL
LIBRARY


Pharmacy
RM
300
A653
3rd ed.
Suppl. 3

SERIAL

**CUMULATIVE
SUPPLEMENT 3
AUG '82 - NOV '82**



REFERENCE



**APPROVED
PRESCRIPTION
DRUG PRODUCTS**

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

3RD EDITION

The University
of Michigan
Pharmacy
Library

FEB 18 1983

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

DEPOSITED BY THE
UNITED STATES OF AMERICA

**FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT**

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 3rd Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "List". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the Addendum: DESI Pending List.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1982. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >add> to the left of the line on which new information exists. The >add> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol ~~>DLT>~~ (DELETE) to the left of the line containing the overstruck print. The ~~>DLT>~~ symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge () to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. INDICES AND ABBREVIATIONS:

STANDARD TERMS:

Added Route of Administration: INTRAPERITONEAL

B. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts (pending adjustments to accommodate errata) derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month and the past quarter.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '82. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts (pending adjustments to accommodate errata) in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

A. COUNTS CUMULATIVE BY QUARTERS	
CATEGORIES COUNTED	JULY '82 (BASELINE)
DRUG PRODUCTS LISTED	6303
SINGLE SOURCE	1885 (30%)
MULTISOURCE (1)	1899 (29.6%)
HERAPEUTICALLY EQUIVALENT	4418 (70%)
MULTISOURCE (1)	4503 (70.4%)
NOT THERAPEUTICALLY EQUIVALENT	3456 (54.8%)
EXCEPTIONS (2)	954 (15.1%)
NEW MOLECULAR ENTITIES APPROVED	3532 (55.2%)
NUMBER OF APPLICANTS	-
303	302
8	8

B. ACTIVITY FOR SUPPLEMENT NUMBER 3 AND CUMULATIVE SINCE OCTOBER '82	
CUMULATIVE	NOV '82
DRUG PRODUCTS ADDED:	48
NEWLY APPROVED	48
DESI EFFECTIVE	48
REMARKETED	0
DRUG PRODUCTS REMOVED:	10
WITHDRAWN APPROVAL	0
RX TO OTC SWITCH	0
DISCONTINUED MARKETING	10
NET GAIN IN DRUG PRODUCTS	38
SINGLE SOURCE PRODUCTS APPROVED	10
MULTISOURCE DRUG PRODUCTS APPROVED	38
NEW MOLECULAR ENTITIES APPROVED	4
AS THE ENTITY	2
AS A SALT, ESTER OR DERIVATIVE	2
OF THE ENTITY	2
FROM MORE THAN ONE APPLICANT	(2)
AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)	(2)

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (i.e., AVAILABLE

FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)

APPROVED PRESCRIPTION DRUG PRODUCTS
DRUG PRODUCT LIST
CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

1

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL

ACETAMINOPHEN W/ CODEINE PHOSPHATE

/AA/ /CARNRICK/SW. CARNRICK/325MG;30MG/

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL

TALACEN

STERLING DRUG

650MG;EQ 25MG BASE*

ACETAZOLAMIDE (PAGE 3-3)

TABLET; ORAL

ACETAZOLAMIDE

AB ASCOT HOSP PHARMS 250MG*

ACYCLOVIR SODIUM (PAGE 3-4)

INJECTABLE; INJECTION

ZOVIRAX

BURROUGHS WELLCOME EQ 500MG BASE/VIAL*

ALUMINIUM CHLORHYDROXY ALLANTOINATE; PREDNISOLONE (PAGE 3-5)

/CREAM; TOPICAL/

/METI-DERM/

/SCHERING/

/0.25%;0.5%/

ALUMINIUM NICOTINATE (PAGE 3-5)

/TABLET; ORAL/

/NICALEX/

/MERRELL POW/POW CHEM/625MG/

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION

HEPATAMINE 8%

AM MCGAW/AM HOSP 8%*

NOVAMINE 8.5%

CUTTER LABORATORIES 8.5%*

NOVAMINE 11.4%

CUTTER LABORATORIES 11.4%*

RENAMIN W/O ELECTROLYTES

TRAIVENOL LABS 6.5%*

AMINOCAPROIC ACID (PAGE 3-7)

INJECTABLE; INJECTION

AMICAR

AP LEDERLE PARENTERALS 250MG/ML

AP AMINOCAPROIC ACID

ELKINS-SINN/AHROBINS 250MG/ML*

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE (PAGE 3-11)

CAPSULE; ORAL

DELCOBESE

/DELCO CHEMICAL/

/1.25MG;1.25MG;1.25MG;1.25MG/

/2.5MG;2.5MG;2.5MG;2.5MG/

/3.75MG;3.75MG;3.75MG;3.75MG/

/5MG;5MG;5MG;5MG/

LEMMON 1.25MG;1.25MG;1.25MG;1.25MG

2.5MG;2.5MG;2.5MG;2.5MG

3.75MG;3.75MG;3.75MG;3.75MG

5MG;5MG;5MG;5MG

TABLET; ORAL

DELCOBESE

/DELCO CHEMICAL/

/1.25MG;1.25MG;1.25MG;1.25MG/

/2.5MG;2.5MG;2.5MG;2.5MG/

/3.75MG;3.75MG;3.75MG;3.75MG/

/5MG;5MG;5MG;5MG/

LEMMON 1.25MG;1.25MG;1.25MG;1.25MG

2.5MG;2.5MG;2.5MG;2.5MG

3.75MG;3.75MG;3.75MG;3.75MG

5MG;5MG;5MG;5MG

ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENONE HYDROCHLORIDE (PAGE 3-15)

CAPSULE; ORAL

PROPOXYPHENONE HCL COMPOUND '65/

/AA/ /ROXANE LABORATORIES//227MG;32.4MG;162MG;65MG/

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE (PAGE 3-16)

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

WINTHROP LABS/STERL 0.4MG/ML;50MG/ML*

0.4MG/ML;75MG/ML*

0.4MG/ML;100MG/ML*

MEPERIDINE AND ATROPINE SULFATE

WYETH LABS/AMHO 0.4MG/ML;50MG/ML

0.4MG/ML;75MG/ML

0.4MG/ML;100MG/ML

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

ACLOCLILIN SODIUM (PAGE 3-17)

INJECTABLE; INJECTION CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM

/INJECTABLE; INJECTION/

CHLORIDE; SODIUM LACTATE (PAGE 3-25)

SOLUTION; INTRAPERTONEAL

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

TRAVENOL LABS 25.7MG/100ML; 5.08MG/100ML; 4.25G/100ML

DIAHEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

5.08MG/100ML; 5.525G/100ML; 4.48G/100ML

ONITEMET; OPTHALMIC

BACTRAGAN ZINC-NEOMYCIN-POLMYXIN

BACTRAGAN ZINC; NEOMYCIN SULFATE; POLMYXIN B SULFATE

(PAGE 3-18)

DAHNEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

5.08MG/100ML; 5.525G/100ML; 4.48G/100ML

TRAVENOL LABS 25.7MG/100ML; 4.25G/100ML

DIAHEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

5.08MG/100ML; 5.525G/100ML; 4.48G/100ML

MILES PHARMS/MILES EA 26M BASE/VIAL*

EA 36M BASE/VIAL*

AZLIN MILES PHARMS/MILES

EA 46M BASE/VIAL*

BACTRAGAN ZINC; NEOMYCIN SULFATE; POLMYXIN B SULFATE

(PAGE 3-18)

DAHNEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

5.08MG/100ML; 5.525G/100ML; 4.48G/100ML

TRAVENOL LABS 25.7MG/100ML; 4.25G/100ML

DIAHEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

5.08MG/100ML; 5.525G/100ML; 4.48G/100ML

BACTRAGAN ZINC-NEOMYCIN-POLMYXIN

AT 400 UNITS/GM; EG 3.5MG BASE/GM;

BACTRAGAN ZINC-NEOMYCIN SULFATE-POLMYXIN B SULFATE

AT 10,000 UNITS/GM;

BETAMETHASONE VALERATE (PAGE 3-20)

AT ABOTT LABORATORIES 25.7MG/100ML; 4.25G/100ML;

INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

5.08MG/100ML; 5.525G/100ML; 4.48G/100ML

ABOTT LABORATORIES 25.7MG/100ML; 4.25G/100ML;

INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

SODIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;

CALCIUM CHLORIDE

SODIUM CHLORIDE (PAGE 3-26)

/AEROSOL; TOPICAL/

/VALISONE/

AT 6.15%/

BROMPHENIRAMINE MALEATE (PAGE 3-21)

SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

/AEROSOL; INHALATION/

PLEGISOL IN PLASTIC CONTAINER

/AEROSOL; INHALATION/

SODIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE;

/DLT /AA/ /CDP; LABORATORIES/ /2MG/5ML/

ELIXIR; ORAL BUTABARBITAL SODIUM (PAGE 3-23)

SODIUM CHLORIDE (PAGE 3-26)

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

AM MCGAW/AM HOSP 20MG/100ML; 30MG/100ML; 360MG/100ML;

RINGER'S IN PLASTIC CONTAINER

AM MCGAW/AM HOSP 33MG/100ML; 360MG/100ML; 860MG/100ML

> ADD > AM MCGAW/AM HOSP 33MG/100ML; 360MG/100ML;

INJECTABLE; INJECTION

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE (PAGE 3-26)

/BUTAPERAZINE Maleate (PAGE 3-23)

/AEROSOL; ORAL/

/AH, ROBINSON/

/REFRESH/

/ED. 25HS, BASE/

/AH, ROBINSON/

/REFRESH/

/AA, ROBINSON/

/REFRESH/

/AH, ROBINSON/

/REFRESH/

/ED. 25HS, BASE/

/AH, ROBINSON/

/REFRESH/

/AA, ROBINSON/

/REFRESH/

/AH, ROBINSON/

/REFRESH/

/ED. 25HS, BASE/

/AH, ROBINSON/

/REFRESH/

/AA, ROBINSON/

/REFRESH/

/AH, ROBINSON/

/REFRESH/

/ED. 25HS, BASE/

/AH, ROBINSON/

/REFRESH/

/AA, ROBINSON/

/REFRESH/

/AH, ROBINSON/

/REFRESH/

/ED. 25HS, BASE/

/AH, ROBINSON/

/REFRESH/

/AA, ROBINSON/

/REFRESH/

/AH, ROBINSON/

/REFRESH/

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

3

CALCIUM GLUCEPTATE (PAGE 3-26)

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE

AP INTL MEDICATION SYS EQ 90MG CALCIUM/5MLX

/CÉLÜSTÉRONE (PAGE 3-26)

/TABLET; ORAL/
/METHOSARB/
/UP JOHN/ /50MG/

> ADD > CEFOPERAZONE SODIUM (PAGE 3-29)

> ADD > INJECTABLE; INJECTION
> ADD > CEFOBID
> ADD > ROERIG/PFIZER EQ 1GM BASE/VIALX
> ADD > EQ 2GM BASE/VIALX

CHLORAMPHENICOL SODIUM SUCCINATE (PAGE 3-31)

> ADD > INJECTABLE; INJECTION
CHLORAMPHENICOL
> ADD > AP ELKINS-SINN/AHROBINS EQ 1GM BASE/VIALX
CHLORAMPHENICOL SODIUM SUCCINATE
AP LYPHO-MED EQ 1GM BASE/VIALX

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-32)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /FEDERAL PHARMACAL/ /5MG/
/AB/ /10MG/
/AB/ /25MG/
AB LEMMON 5MG
AB 10MG
AB 25MG

CHLORTIAZIDE (PAGE 3-33)

TABLET; ORAL
CHLORTIAZIDE
AB BOLAR PHARMACEUTICAL 500MGX
/AB/ /FEDERAL PHARMACAL/ /250MG/
AB LEMMON 250MG

CHLORPHENIRAMINE MALEATE (PAGE 3-34)

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE
> DLT >/AP/ /CARTER-GLOBAU LABS/ /10MG/ML/
> DLT >/AP/ /100MG/ML/

SYRUP; ORAL
HISTREY/
/AA/ /BOWMAN PHARMS/ /2MG/5ML/

CHLORPROMAZINE HYDROCHLORIDE (PAGE 3-35)

TABLET; ORAL
CHLORPROMAZINE HCL
BP VANGARD LABS/MWM 10MGX
BP WEST-WARD 10MGX
BP 25MGX
BP 50MGX
BP 100MGX
BP 200MGX

CHLORTHALIDONE (PAGE 3-37)

TABLET; ORAL
CHLORTHALIDONE
AB ASCOT HOSP PHARMS 25MGX
AB 50MGX
> ADD > THALITONE
> ADD > AB BOEHRINGER INGELHEIM 25MGX

CHLORZOXAZONE (PAGE 3-37)

TABLET; ORAL
CHLORZOXAZONE
AA CHELSEA LABORATORIES 250MGX

> ADD > CHYMOPAPAIN (PAGE 3-37)

> ADD > INJECTABLE; INJECTION
> ADD > CHYMODIACTIN
> ADD > SMITH LABORATORIES 10,000 UNITS/VIALX

CYCLOPHOSPHAMIDE (PAGE 3-44)

INJECTABLE; INJECTION
CYTOXAN
MEAD JOHNSON/B-M 1GM/VIALX
2GM/VIALX

> ADD > AA	BAY LABORATORIES	2MG/5MLx	SYRUP; ORAL	CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-44)
> ADD >	DEXTROSE 6oz	AM MCGAW/AM HOSP	DEXTROSE; POTASSIUM CHLORIDE (PAGE 3-52)	TABLET; ORAL
> ADD >	AM MCGAW/AM HOSP	5GM/100ML; 25MG/100MLx	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	DEXTROSE; POTASSIUM CHLORIDE (PAGE 3-47)
> ADD > AP	TRAVERSOL LABS	5GM/100ML; 25MG/100MLx	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	DEXTROSE; POTASSIUM CHLORIDE (PAGE 3-48)
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 25MG/100MLx	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	DEXTROSE SODIUM PHOSPHATE (PAGE 3-48)
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 224MG/100MLx	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	DEXTROSE SODIUM PHOSPHATE/MIL ELKINS-SINN/AHROBINS EG 4MG PHOSPHATE/HL
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 500MG/100MLx	DEXTROSE MEGLUMINE (PAGE 3-54)	DEXTROZATE MEGLUMINE (PAGE 3-54)
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 500MG/100MLx	DEXTROZATE MEGLUMINE (PAGE 3-54)	INJECTABLE; INJECTION /ELKINS-SINN/AHROBINS EG 4MG PHOSPHATE/HL
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 500MG/100MLx	INJECTABLE; INJECTION /ELKINS-SINN/AHROBINS EG 4MG PHOSPHATE/HL	INJECTABLE; INJECTION /ELKINS-SINN/AHROBINS EG 4MG PHOSPHATE/HL
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 500MG/100MLx	INJECTABLE; INJECTION /ELKINS-SINN/AHROBINS EG 4MG PHOSPHATE/HL	SOLUTION/DROPS; OPTHALMIC /BARNES-HIND PHARMS EG 0.1% PHOSPHATE
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 500MG/100MLx	INJECTABLE; INJECTION /ELKINS-SINN/AHROBINS EG 4MG PHOSPHATE/HL	SOLUTION/DROPS; OPTHALMIC /DEGARDEN EG 0.1% PHOSPHATE
> ADD > AP	AM MCGAW/AM HOSP	5GM/100ML; 500MG/100MLx	INJECTABLE; INJECTION /DEGARDEN EG 0.1% PHOSPHATE	MURRY BIOLOGICAL EG 0.1% PHOSPHATE
> ADD > AT	BERLEX/SCHERING AG	3024x	INJECTABLE; INJECTION /DEGARDEN EG 0.1% PHOSPHATE	/TABLET; CONTROLLLED RELEASE; DRUG/
> ADD > AT	BERLEX/SCHERING AG	3024x	INJECTABLE; INJECTION /DISSOPHOL /SCHEFING /	/TABLET; CONTROLLLED RELEASE; DRUG/
> ADD > AT	BERLEX/SCHERING AG	3024x	INJECTABLE; INJECTION /ANGIOVIST 292	/SCHEFING /
> ADD > AP	BERLEX/SCHERING AG	5224:624x	INJECTABLE; INJECTION /ANGIOVIST 370	/ANGIOVIST 370
> ADD > AP	BERLEX/SCHERING AG	6624:1024x	INJECTABLE; INJECTION /ANGIOVIST 292	ANGIOVIST 370
> ADD > AP	BERLEX/SCHERING AG	6624:1024x	SOLUTION; ORAL, RECTAL /ANGIOVIST 370	SOLUTION; ORAL, RECTAL /ANGIOVIST 370
> ADD > AA	BERLEX/SCHERING AG	6624:1024x	SOLUTION; ORAL, RECTAL /ANGIOVIST 370	BERLEX/SCHERING AG 6624:1024x
				BERLEX/SCHERING AG 6624:1024x

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

5

DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
UROVIST SODIUM 300
AP BERLEX/SCHERING AG 50%*

> ADD > DILTIAZEM HYDROCHLORIDE (PAGE 3-57)

> ADD > TABLET; ORAL
> ADD > CARDIZEM
> ADD > MARION LABORATORIES EQ 30MG BASE*
> ADD > EQ 60MG BASE*

DIMENHYDRINATE (PAGE 3-57)

INJECTABLE; INJECTION
DIMENHYDRINATE
/AP/ /CENTRAL PHARMS/ /50MG/ML/

/SUPPOSITORY; RECTAL/
/DRAZAMINE/
/SEARLE PHARMS/ /100MG/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-58)

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
/AA/ /PREMO PHARM LABS/ /25MG/
/AA/ /VANGARD LABS/MWM 50MG/
AA VANGARD LABS/MWM 25MG*

DOPAMINE HYDROCHLORIDE (PAGE 3-60)

INJECTABLE; INJECTION
DOPAMINE HCL
AP ABBOTT LABORATORIES 80MG/ML*

DOXYCYCLINE HYCLATE (PAGE 3-61)

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
AB DANBURY PHARMACAL EQ 50MG BASE*
AB EQ 100MG BASE*

TABLET; ORAL
DOXYCYCLINE HYCLATE
AB BARR LABORATORIES EQ 100MG BASE*

DYDROGESTERONE (PAGE 3-61)

TABLET; ORAL
DYDROGESTERONE
/BP/ /ROXANE LABORATORIES/ /5MG/
/BP/ /10MG/

GYMOREST
/BP/ MEAD JOHNSON/B-M 5MG
/BP/ 10MG

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE (PAGE 3-62)

INJECTABLE; INJECTION
/DURANEST W/ EPINEPHRINE/
DURANEST

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-63)

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE
ASTRA PHARM PRODS 0.005MG/ML; 0.5%*

ERGOLOID MESYLATES (PAGE 3-63)

TABLET; ORAL
ERGOLOID MESYLATES
AB DANBURY PHARMACAL 1MG*

TABLET; SUBLINGUAL
ALKERGOT
/AA/ /PREMO PHARM LABS/ /0.5MG/
/AA/ /1MG/
AA LEMMON 0.5MG
AA 1MG
AA H.E.A. VANGARD LABS/MWM 0.5MG*
AA 1MG*

ERYTHROMYCIN (PAGE 3-64)

SOLUTION; TOPICAL
> ADD > A/T/S
> ADD > AT HOECHST-ROUSSEL 22%

ERYTHROMYCIN ESTOLATE (PAGE 3-64)

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE
> ADD > AB NATL PHARM MFG/BARRE EQ 125MG BASE/5ML*

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

6

ERYTHROMYCIN ESTOLATE (PAGE 3-64)

SUSPENSION; ORAL

> ADD > AB DISSTA PRODS/LILLY EQ 125MG BASE/ML

INJECTABLE; INJECTION

FACTREL

AYERST LABS/AMHO EQ 0.1MG BASE/VIAL

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

AT PHARMAFAIR 0.025MG/ML; EQ 1.75MG BASE/ML;

0.025MG/ML; EQ 1.75MG BASE/ML;

0.025MG/ML; EQ 1.75MG BASE/ML;

10,000 UNITS/ML;

GUANABENZ ACETATE (PAGE 3-78)

ETOHIMATE (PAGE 3-71)

INJECTABLE; INJECTION

WYETH INC

MYETH LABS/AMHO EQ 4MG BASE

HALOPERIDOL (PAGE 3-78)

> ADD > AP AMBOTT LABORATORIES 2MG/ML

INJECTABLE; INJECTION

(Dihydrofuran-2-yl)/

/Aleft, Oral-28/

/DEHUILEN-FE-28/

/SEARLE/SEARLE, PHARMS/6.5MG; 11.5G; 15MG/

GUANABENZ ACETATE (PAGE 3-78)

ETOHIMATE (PAGE 3-71)

> ADD > AP HYPERMIDE JANSSEN PHARMA 2MG/ML

TABLET, CONTROLLED RELEASE; ORAL

/MCNeil, LABORATORIES//5MG/ML/

/Haldol/

/INJECTABLE; INJECTION

CONECENTRATE; ORAL

MCNEIL LABORATORIES EQ 2MG BASE/ML

HALDOL

INJECTABLE; INJECTION

GENERIC SULFATE (PAGE 3-76)

> ADD > AP CARTER-GELOGAU LABS 50MG/ML

FLUOROURACIL

INJECTABLE; INJECTION

MCNEIL LABORATORIES EQ 2MG BASE/ML

HALDOL

INJECTABLE; INJECTION

GENERIC SULFATE (PAGE 3-76)

> ADD > AP TRAVENOL LABS EQ 80MG BASE/100ML

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

INJECTABLE; INJECTION

/Aleft/

/SEARLE, PHARMS/

/50 UNITS/ML/

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

7

HYALURONIDASE (PAGE 3-82)

INJECTABLE; INJECTION

WYDASE

/AB/ /WYETH LABS/AMHO/ /150 UNITS/VIAL/
WYETH LABS/AMHO 150 UNITS/VIAL

HYDRALAZINE HYDROCHLORIDE (PAGE 3-82)

TABLET; ORAL

HYDRALAZINE HCL

/AA/ PAR PHARMACEUTICALS /10MG/
/AA/ /PREMO PHARM LABS/ /25MG/
/AA/ LEMMON /50MG/
AA 50MG

HYDROCHLORTIAZIDE (PAGE 3-83)

TABLET; ORAL

HYDROCHLORTIAZIDE

> DLT > AB ROXANE LABORATORIES /25MG/

HYDROCORTISONE (PAGE 3-85)

LOTION; TOPICAL

NUTRACORT

/AT/ /OWEN LABS/ALCON LABS/0.5%/
/AT/ /12/
AT OWEN LABS/DERM PRODS 0.5%
AT 12
2.5%

OINTMENT; TOPICAL

HYMAC

AT NMC LABS 12%

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-88)

SOLUTION; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

AT PHARMAFAIR 12;EQ 3.5MG BASE/ML;10,000 UNITS/ML
SUSPENSION; OTIC
OTICAIR
AT PHARMAFAIR 12;EQ 3.5MG BASE/ML;10,000 UNITS/ML

HYDROCORTISONE BUTYRATE (PAGE 3-89)

OINTMENT; TOPICAL

LOCOID

GIST-BROCADES/NETH 0.1%

HYDROXOCOBALAMIN (PAGE 3-90)

INJECTABLE; INJECTION

ALPHA-RUVITÉ

/AB/ /SAVAGE LABS/BYK-SIÖN/1MG/ML/

HYDROXYZINE HYDROCHLORIDE (PAGE 3-91)

TABLET; ORAL

HYDROXYZINE HCL

/AB/ /PREMO PHARM LABS/ /50MG/
AB LEMMON 50MG

HYDROXYZINE PAMOATE (PAGE 3-91)

CAPSULE; ORAL

HY-PAM

/AB/ /PREMO PHARM LABS/ /EQ 25MG HCL/
/AB/ /EQ 50MG HCL/
AB LEMMON EQ 25MG HCL
AB EQ 50MG HCL
HYDROXYZINE PAMOATE
AB CHELSEA LABORATORIES EQ 100MG HCL
AB DANBURY PHARMACAL EQ 50MG HCL
AB EQ 100MG HCL

IMIPRAMINE HYDROCHLORIDE (PAGE 3-92)

TABLET; ORAL

IMIPRAMINE HCL

/AB/ /PREMO PHARM LABS/ /10MG/
/AB/ /25MG/
/AB/ /50MG/
AB LEMMON 10MG
AB 25MG
AB 50MG
> ADD > AB VANGARD LABS/MWM 10MG

TODAMATE MÉGLUMINÉ (PAGE 3-93)

INJECTABLE; INJECTION

DIMERAY

/MALLINCKRODT/ /500MG/ML/

IPODATE SODIUM (PAGE 3-95)
CAPSULE; ORAL
CHLORIDE; SODIUM GLUCONATE (PAGE 3-103)
MANGANESE CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM

ISOTETHARINE HYDROCHLORIDE (PAGE 3-95)
SOLUTION; INHALATION
ISOTERPENTOL HCl
ARMOUR PHARM 0.125%
0.062%
0.031%
> ADD > AP INVENEX LABS/DEXTER 0.2MG/ML
> DLT > /DLT/ /TFR/ /VITAMIN/WST/CHF/ /6.2MG/ML/
TABLET; ORAL
LUDOMILL
CIBA/CIBA-GEIGY 75MG
MEPIVACAINE HYDROCHLORIDE (PAGE 3-107)

ISOSROTENEROL HYDROCHLORIDE (PAGE 3-97)
SOLUTION; INJECTION
ISOSROTENEROL HCl
ARMOUR PHARM 0.125%
0.062%
0.031%
> ADD > AP INVENEX LABS/DEXTER 0.2MG/ML
> DLT > /DLT/ /TFR/ /VITAMIN/WST/CHF/ /6.2MG/ML/
TABLET; ORAL
LUDOMILL
CIBA/CIBA-GEIGY 75MG
MEPIVACAINE HYDROCHLORIDE (PAGE 3-107)

ISOSROTENEROL HYDROCHLORIDE (PAGE 3-97)
SOLUTION; INJECTION
ISOSROTENEROL HCl
ARMOUR PHARM 0.125%
0.062%
0.031%
> ADD > AN ROXANE LABORATORIES 0.125%
0.062%
0.031%
> ADD > AN ROXANE LABORATORIES 0.125%
0.062%
0.031%
TABLET; ORAL
LOTION; TOPICAL
PURDUE FREDERICK 0.5%
PRIDERM
PURDUE FREDERICK 0.5%
MEPIVACAINE HYDROCHLORIDE (PAGE 3-107)

ISOSROTENEROL HYDROCHLORIDE (PAGE 3-97)
SOLUTION; INJECTION
ISOSROTENEROL HCl
ARMOUR PHARM 0.125%
0.062%
0.031%
> ADD > AP INVENEX LABS/DEXTER 0.2MG/ML
> DLT > /DLT/ /TFR/ /VITAMIN/WST/CHF/ /6.2MG/ML/
TABLET; ORAL
LUDOMILL
CIBA/CIBA-GEIGY 75MG
MEPIVACAINE HYDROCHLORIDE (PAGE 3-107)

LEUCOVORIN CALCIUM (PAGE 3-98)
INJECTABLE; INJECTION
GARBOGATNE
BREON LABS/STERLING 12
AP MEPIVACAINE HCl
INTL MEDICATION Sys 12m
MEPROBAMATE (PAGE 3-107)

LEUCOVORIN CALCIUM (PAGE 3-98)
INJECTABLE; INJECTION
GARBOGATNE
BREON LABS/STERLING 12
AP MEPIVACAINE HCl
INTL MEDICATION Sys 12m
MEPROBAMATE (PAGE 3-107)

LIDOCAINE HYDROCHLORIDE (PAGE 3-100)
SOLUTION; ORAL
METHDONE HCl
ROXANE LABORATORIES 10MG/5MLx
METDANOINE HYDROCHLORIDE (PAGE 3-110)

LIDOCAINE HYDROCHLORIDE (PAGE 3-100)
SOLUTION; ORAL
METHDONE HCl
ROXANE LABORATORIES 10MG/5MLx
METDANOINE HYDROCHLORIDE (PAGE 3-110)

ADD > AI BAY LABORATORIES 22m
SOLUTION; TOPICAL
BAYLOGCAINE
BAY LABORATORIES 62m
> ADD > AI BAY LABORATORIES 22m

ADD > AI BAY LABORATORIES 62m
SOLUTION; TOPICAL
BAYLOGCAINE
BAY LABORATORIES 62m
> ADD > AI BAY LABORATORIES 62m

ADD > AI BAY LABORATORIES 62m
SOLUTION; TOPICAL
BAYLOGCAINE
BAY LABORATORIES 62m
> ADD > AI BAY LABORATORIES 62m

ADD > AI BAY LABORATORIES 62m
SOLUTION; TOPICAL
BAYLOGCAINE
BAY LABORATORIES 62m
> ADD > AI BAY LABORATORIES 62m

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

9

METHOCARBAMOL (PAGE 3-112)

TABLET; ORAL
METHOCARBAMOL
AA ASCOT HOSP PHARMS 500MG~~x~~
AA 750MG~~x~~

METHYCLOTHIAZIDE (PAGE 3-114)

TABLET; ORAL
METHYCLOTHIAZIDE
AB MYLAN PHARMS 2.5MG~~x~~
AB 5MG~~x~~

METHYLPREDNISOLONE ACETATE (PAGE 3-115)

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE
BP MAURRY BIOLOGICAL 40MG/ML~~x~~
BP 80MG/ML~~x~~

METHYLTESTOSTERONE (PAGE 3-115)

CAPSULE; ORAL
METHYLTESTOSTERONE
> ADD > BP HEATHER DRUG 10MG
VIRILON
> DLT > /BP/ /HEATHER DRUG/ /10MG/
> ADD > BP STAR PHARMACEUTICALS 10MG~~x~~

TABLET; ORAL
METHYLTESTOSTERONE
> ADD > BP LANNETT 10MG~~x~~

METRONIDAZOLE (PAGE 3-117)

INJECTABLE; INJECTION
METRO I.V.
AP AM MCGAW/AM HOSP 500MG/100ML~~x~~

TABLET; ORAL
METRONIDAZOLE
AB CHELSEA LABORATORIES 250MG~~x~~
AB CORD LABORATORIES 250MG~~x~~
AB 500MG~~x~~
AB DANBURY PHARMACAL 250MG~~x~~
/AB/ /LEMON/ 250MG
AB METRYL 250MG
AB LEMMON 250MG

MINOCYCLINE HYDROCHLORIDE (PAGE 3-118)

TABLET; ORAL
MINOCIN
LEDERLE LABS/AM CYAN EQ 50MG BASE~~x~~
EQ 100MG BASE~~x~~

> DLT > /MITRAMYCIN/ (PAGE 3-118)
> ADD > PLICAMYCIN

NYSTATIN (PAGE 3-123)

OINTMENT; TOPICAL
NYSTATIN
AT BYK-GULDEN 100,000 UNITS/GM~~x~~

/OXOLINIC ACID/ (PAGE 3-125)

/TABLET; ORAL/
/OTC/ /PARKER-DAVIS/W.L./ /150MG/

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-126)

CAPSULE; ORAL
OXYTETRACYCLINE HCL
/AB/ /LEDERLE LABS/AM CYAN/EQ 250MG BASE/

PENICILLIN G POTASSIUM (PAGE 3-128)

TABLET; ORAL
PENICILLIN G POTASSIUM
> DLT > AB /JOHN P. COFANO'S/ /100,000 UNITS/
> DLT > AB / /200,000 UNITS/
> DLT > AB / /250,000 UNITS/
> DLT > AB / /400,000 UNITS/
> DLT > AB / /500,000 UNITS/

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE
/AB/ /CORD LABORATORIES/ 35MG
AA REID-PROVIDENT LABS 35MG
AA X-TROZINE REXAR PHARMACAL 35MG~~x~~

PROPANTHELINE BROMIDE (PAGE 3-146)

TABLET; ORAL

PROPANTHELINE BROMIDEAA ASCOT HOSP PHARMS 15MG#PROPARACAIN HYDROCHLORIDE (PAGE 3-146)

SOLUTION/DROPS; OPHTHALMIC

PARACAINAT PRO PHARMA/STERI-MED 0.5%#PROPOXYPHENE HYDROCHLORIDE (PAGE 3-147)

CAPSULE; ORAL

PROPOXYPHENE HCL/AA /FREMO PHARM LABS/ 65MG/AA LEMMON 65MG/AA /ROXANE LABORATORIES/ 65MG/PYRIDOXINE HYDROCHLORIDE (PAGE 3-149)

INJECTABLE; INJECTION

PYRIDOXINE HCLAP MAURRY BIOLOGICAL 100MG/ML#QUINIDINE GLUCONATE (PAGE 3-150)

TABLET, CONTROLLED RELEASE; ORAL

QUINIDINE GLUCONATEAB DANBURY PHARMACAL 324MG#SISOMICIN SULFATE (PAGE 3-155)

/INJECTABLE; INJECTION/

SISEPIN/SCHERRING/ /50MG/ML/SODIUM CHLORIDE (PAGE 3-155)

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT LABORATORIES 9MG/ML#SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP ABBOTT LABORATORIES 9MG/ML#SPIRONOLACTONE (PAGE 3-159)

TABLET; ORAL

SPIRONOLACTONEAB ASCOT HOSP PHARMS 25MG#
> ADD > AB PARKE-DAVIS/W-L 25MG#SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE; UREA (PAGE 3-160)

CREAM; VAGINAL

SULHACAT NMC LABORATORIES 3.7%:2.86%:3.42%:0.64%#TRIPLE SULFA> ADD > AT CLAY-PARK LABS 3.7%:2.86%:3.42%:0.64%#SULFAMETER (PAGE 3-161)

/TABLET; ORAL/

SULLA/BERLEX/SCHERRING/ /500MG/SULFAMETHOXAZOLE (PAGE 3-161)

TABLET; ORAL

SULFAMETHOXAZOLEAB ASCOT HOSP PHARMS 500MG#SULFINPYRAZONE (PAGE 3-162)

CAPSULE; ORAL

ANTURANEAB CIBA/CIBA-GEIGY 200MGSULFINPYRAZONEAB BARR LABORATORIES 200MG#ZENITH LABORATORIES 200MG#

> ADD > AB

TABLET; ORAL

SULFINPYRAZONEAB BARR LABORATORIES 100MG#SULFISOXAZOLE (PAGE 3-162)

TABLET; ORAL

SULFISOXAZOLE/BP/ /FREMO PHARM LABS/ /500MG/BP LEMMON 500MG

INJECTABLE; INJECTION	AMERSHAM/RADIOCHEM	N/Ax	TRIACRYLICNE (PAGE 3-164)
LOTION; TOPICAL	KERALOGS	ER SQUIBB AND SONS	TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)
INJECTABLE; INJECTION	AMERSCAN	AT	TECHNETIUM TC-99M SULFUR COLLOID (PAGE 3-165)
DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82	AT	0.025%	/SYNCH. INT/ /ACT/M/
TECHNETIUM, TC-99M, MEDRONATE KIT (PAGE 3-164)	AT	0.12%	INJECTABLE; INJECTION
TRIACRYLICNE ACETONIDE (PAGE 3-164)	AT	0.025%	TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)
TERACYCLINE (PAGE 3-166)	SYRUP; ORAL	/64.125mg HgL/500L/	TERACYCLINE (PAGE 3-166)
TRICHLOROMETIAZIDE (PAGE 3-174)	TABLET; ORAL	/BP/ /Pfizer, LABORATORIES//60mg/	THEOPHYLLINE (PAGE 3-168)
TRICHLOROMETIAZIDE (PAGE 3-175)	SYRUP; ORAL	/66.667mg HgL/500L/	THEOPHYLLINE (PAGE 3-168)
TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-169)	TABLET; ORAL	SLD-PHYLLIN	AA WILLIAM H RORER 80MG/15ML
ZENITH LABORATORIES EG 1MG BASE	> ADD > AB	/Pd/ /Pd/Pd/	AA WILLIAM H RORER 100MG
EG 2MG BASE	> ADD > AB	/Z/	BD WILLIAM H RORER 100MG
EQ 1MG BASE	> ADD > AB	/Z/	PURDUE FREDERICK 400MGx
EQ 2MG BASE	> ADD > AB	/Z/	THEOCOINTIN
TRIFLUOPERAZINE HCl	TRIFLUOPERAZINE HCl	TABLET, CONTROLLED RELEASE; ORAL	THIAHINE HCl
ZENITH LABORATORIES EG 1MG BASE	TRIFLUOPERAZINE HCl	TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-176)	INJECTABLE; INJECTION
EG 2MG BASE	ZENITH LABORATORIES EG 1MG BASE	TABLET; ORAL	TRIAMCINOLONE ACETONIDE (PAGE 3-173)
EQ 1MG BASE	ZENITH LABORATORIES EG 1MG BASE	TRIAMCINOLONE ACETONIDE (PAGE 3-173)	AT PHARMAFAIR 0.025%
EQ 2MG BASE	ZENITH LABORATORIES EG 1MG BASE	TABLET; ORAL	AT TRIAMCINOLONE ACETONIDE
EQ 1MG BASE	ZENITH LABORATORIES EG 1MG BASE	TRIAMCINOLONE ACETONIDE (PAGE 3-176)	AT 0.12%
TRIAMCINOLONE ACETONIDE (PAGE 3-176)	TRIAMCINOLONE ACETONIDE (PAGE 3-176)	TRIAMCINOLONE ACETONIDE (PAGE 3-176)	0.57%
TRIAMCINOLONE ACETONIDE (PAGE 3-176)	TRIAMCINOLONE ACETONIDE (PAGE 3-176)	TRIAMCINOLONE ACETONIDE (PAGE 3-176)	AT
TRIAMCINOLONE ACETONIDE (PAGE 3-176)	TRIAMCINOLONE ACETONIDE (PAGE 3-176)	TRIAMCINOLONE ACETONIDE (PAGE 3-176)	TRIAMCINOLONE ACETONIDE (PAGE 3-176)

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82

13

TRIMETHOPRIM (PAGE 3-176)

TABLET; ORAL
TRIMPEX 200
BX HOFFMANN-LA ROCHE **200MG***

TRIMIPRAMINE MALEATE (PAGE 3-176)

CAPSULE; ORAL
SURMONTIL
IVES LABS/AMHO EQ 100MG BASE*

TROMETHAMINE (PAGE 3-177)

INJECTABLE; INJECTION
THAM
BX ABBOTT LABORATORIES /**36MG/ML/**
BX **3.6GM/100ML**

TROPICAMIDE (PAGE 3-178)

SOLUTION/DROPS; OPHTHALMIC
MYDRIACYL
AT ALCON LABORATORIES **1%**
AT **TROPICAMIDE**
AT PRO PHARMA/STERI-MED **1/2%**

VITAMIN A (PAGE 3-179)

CAPSULE; ORAL
VITAMIN A
/AA/ /LEADER LABS/AM/250/50;600/10/

WARFARIN SODIUM (PAGE 3-180)

TABLET; ORAL
ATHROMBIN
/BP/ /PURDUE FREDERICK/ /5MG/
/BP/ /PURDUE FREDERICK/ /10MG/
BX PURDUE FREDERICK 5MG
BX 10MG
COUMADIN
/BP/ /ENDO LABS/DUPONT/ /2MG/
/BP/ /ENDO LABS/DUPONT/ /2.5MG/
/BP/ /ENDO LABS/DUPONT/ /5MG/
/BP/ /ENDO LABS/DUPONT/ /7.5MG/
/BP/ /ENDO LABS/DUPONT/ /10MG/
BX ENDO LABS/DUPONT 2MG
BX 2.5MG
BX 5MG
BX 7.5MG
BX 10MG

WARFARIN SODIUM (PAGE 3-180)

TABLET; ORAL
PANWARFIN
/BP/ /ABBOTT LABORATORIES/ /2MG/
/BP/ /ABBOTT LABORATORIES/ /2.5MG/
/BP/ /ABBOTT LABORATORIES/ /5MG/
/BP/ /ABBOTT LABORATORIES/ /7.5MG/
/BP/ /ABBOTT LABORATORIES/ /10MG/
BX ABBOTT LABORATORIES 2MG
BX 2.5MG
BX 5MG
BX 7.5MG
BX 10MG

WARFARIN SODIUM
BX BOLAR PHARMACEUTICAL 2MG*
BX 2.5MG*
BX 5MG*
BX 7.5MG*
BX 10MG*

WATER FOR INJECTION, STERILE (PAGE 3-180)

LIQUID; N/A
BACTERIOSTATIC WATER IN PLASTIC CONTAINER
ABBOTT LABORATORIES 100%

XENON, XE-127 (PAGE 3-181)

GAS; INHALATION
XENON XE 127
MALLINCKRODT 5MCIVIAL*
10MCIVIAL*

CURRENT STATUS - INEFFECTIVE
CUMULATIVE SUPPLEMENT NUMBER 3 / AUGUST '82 - NOVEMBER '82
DESI PENDING LIST
ADDENDUM

BUTIBEL /MCNELL LABORATORIES/
BUTIBEL /MCNELL LABS/C-W

DIPYRIDAMOLE /KETODIHYDROFOLATE/
DIPYRIDAMOLE /KETODIHYDROFOLATE/

CURRENT STATUS - EXEMPT. (COURT ORDER)


DIPYRIDAMOLE ASCOT HOSP PHARMS
DIPYRIDAMOLE HALSY DRUG

HYBEHEN BEECHAM LABS/BEECHAM
ATROPINE SULFATE; HYOSCAYAMINE SULFATE; PHENOBARBITAL;
SCOPOLAMINE HYDROBROMIDE

ISOSORBIDE DINITRATE INWOOD LABS/FOREST
METHANDROSOSTERONE PAR PHARMACEUTICAL
NITRO-TIME TIME-CAP LABS

> ADD > NITROGLYCERIN
NITROGLYCERIN VITARINE/WEST CHEM
NITROGLYCERIN PARK-DAVIS/W-L

> ADD > PENTAERYTHRITOL TETRANITRATE INWOOD LABS/FOREST
NITROGLYCERIN





UNIVERSITY OF MICHIGAN